Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04631432
Other study ID # 109171
Secondary ID Technion institu
Status Completed
Phase
First received
Last updated
Start date January 1, 2021
Est. completion date September 13, 2021

Study information

Verified date April 2022
Source Technion, Israel Institute of Technology
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The study aims to replicate and clarify a recently observed phenomenon whereby individuals with Autism Spectrum Disorder (ASD) switch between options in a repeated task to a greater extent than healthy controls do. In a meta-analysis a large effect size was found (.37) yet because the effect was noisy in different studies it was not statistically significant. The investigators seek to first examine a very large population through an Internet mediated platform. The sample size will be about the size of all of the previous studies that examined this issue together. Secondly, the investigators wish to understand the discrepancy between this choice switching phenomenon and the recorded tendency of ASD individuals to avoid changing choices. First, the investigators will administer the task in which the effect was found (the Iowa Gambling task) for a longer duration than previously and evaluate whether ASD individuals show increased choice switching in the first blocks of trials but reduced switching following more experience. Secondly, the investigators will administer an additional block of trials without feedback in which participants will not be able to go through a learning process. The investigators predict that this will reduce (and possible flip) the tendency of individuals with ASD to switch choices more often.


Recruitment information / eligibility

Status Completed
Enrollment 114
Est. completion date September 13, 2021
Est. primary completion date August 13, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - ASD group - Diagnosed with ASD - Control - No ASD diagnosis: within age and education range of the ASD group. Exclusion Criteria: - Demographics: Under 18 years of age. - Mental health: self reported brain injury and neurological disorder (besides autism).

Study Design


Intervention

Diagnostic Test:
Pre-screening
Document upload of Autism diagnosis certificate. Participants can request to show their certificate via a Zoom meeting with the researcher instead of uploading it.
Behavioral:
Task session
The Iowa Gambling task- four decks of cards on the computer screen. Each card yields a reward, but might also yield a loss. In each trial, the participant selects a card. Consequently, the card is exposed, displaying the gain and the loss for that trial. Through contingent feedback, participants are expected to learn that some deck are better than others.The task will include 120 trials. Block of trials without feedback- four decks of cards on the computer screen. Each card yields a reward, but might also yield a loss. In each trial, the participant selects a card. Consequently, the card is exposed, but the gain and the loss for that trial are not displayed. The task will include 30 trials. Social Responsiveness Scale, 2nd Edition (SRS-2; adult-self report):(Constantino & Gruber, 2012) The brief autism quotient scale:(AQ10; Baron-Cohen et al., 2001) Brief intelligence test (Similarities-MAB + Raven Set 1)

Locations

Country Name City State
Israel Technion, Israel Institute of Technology Haifa

Sponsors (1)

Lead Sponsor Collaborator
Technion, Israel Institute of Technology

Country where clinical trial is conducted

Israel, 

References & Publications (4)

Bechara A, Damasio AR, Damasio H, Anderson SW. Insensitivity to future consequences following damage to human prefrontal cortex. Cognition. 1994 Apr-Jun;50(1-3):7-15. — View Citation

Gaeth GJ, Levin IP, Jain G, Data EV. Toward understanding everyday decision making by adults across the autism spectrum. Judgment and Decision Making. 2016 Nov 1;11(6):537.

Ozonoff S. Reliability and validity of the Wisconsin card sorting test in studies of autism. Neuropsychology. 1995;9(4):491.

Zeif D, Yechiam E. Autism is not associated with poor or enhanced performance on the Iowa Gambling Task: A Meta-Analysis. Neurosci Biobehav Rev. 2020 Jun;113:440-447. doi: 10.1016/j.neubiorev.2020.04.016. Epub 2020 Apr 18. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Mean run size Number of consecutive selections from the same deck (across trials and in different blocks). Through study completion, an average of 1 year
Primary Advantageous selections Percentage of advantageous selections(across trials and in different blocks). Through study completion, an average of 1 year
See also
  Status Clinical Trial Phase
Terminated NCT03715166 - Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder Phase 3
Not yet recruiting NCT05182697 - SCI-210 in the Treatment of Children and Young Adults With AutismEvaluate the Safety, Tolerability and Efficacy of SCI-210 in Children With Autism Spectrum Disorder (ASD) N/A
Completed NCT02803801 - Build Your Parenting Toolkit: Guiding Children to Become Flexible Thinkers N/A
Recruiting NCT04376151 - Guided ACT and for Adults With ASD N/A
Terminated NCT03715153 - Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder. Phase 3
Terminated NCT01592773 - Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Phase 2
Withdrawn NCT01395953 - Double-blind Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders Phase 2
Terminated NCT01248130 - Omega-3 Fatty Acids Monotherapy in Children and Adolescents With Autism Spectrum Disorders Phase 2
Completed NCT04860986 - A Repeatability and Reproducibility Study of the EarliPointâ„¢ Device
Active, not recruiting NCT04299464 - A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD) Phase 2
Recruiting NCT03392870 - Evaluation of a Clinical Transitional Program in Autism N/A
Completed NCT01592786 - An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Phase 2
Enrolling by invitation NCT05187377 - A Controlled Trial of Growth Hormone in Phelan-McDermid Syndrome and Idiopathic Autism Phase 2
Recruiting NCT04578756 - Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder Phase 3
Completed NCT02037022 - Pivotal Response Treatment Package for Young Children With Autism N/A
Completed NCT01854346 - Social Skills Group Training ("KONTAKT") for Children and Adolescent With High-functioning Autism Spectrum Disorders N/A
Active, not recruiting NCT04895215 - AB-2004 in Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) Phase 2
Active, not recruiting NCT03426826 - The Gut-Brain Study Phase 1
Completed NCT02384486 - Efficacy of Training Programme to Reduce Stress N/A
Completed NCT00614198 - ScanBrit Dietary Intervention in Autism Phase 2